⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11788167 | 0.69 | — | — | |
| SCHEMBL3800774 | 0.69 | — | — | |
| SCHEMBL7093988 | 0.69 | — | — | |
| SCHEMBL1269155 | 0.69 | — | — | |
| SCHEMBL18423815 | 0.67 | — | — | |
| SCHEMBL9366184 | 0.67 | — | — | |
| SCHEMBL1817629 | 0.67 | — | — | |
| SCHEMBL1579807 | 0.65 | — | — | |
| SCHEMBL11243169 | 0.65 | — | — | |
| SCHEMBL11174465 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215037-A1 | ELECTROCHEMICALLY-CLEAVABLE LINKERS | MICROSOFT TECHNOLOGY LICENSING, LLC | 2025-07-03 | — | — | US | disclosed |
| US-20250215037-A1 | ELECTROCHEMICALLY-CLEAVABLE LINKERS | MICROSOFT TECHNOLOGY LICENSING, LLC | 2025-07-03 | — | — | US | disclosed |
| US-12281134-B2 | Electrochemically-cleavable linkers | MICROSOFT TECHNOLOGY LICENSING, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| US-12281134-B2 | Electrochemically-cleavable linkers | MICROSOFT TECHNOLOGY LICENSING, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250115635-A1 | LINKER STRUCTURES WITH MINIMAL SCAR FOR ENZYMATIC SYNTHESIS | MICROSOFT TECHNOLOGY LICENSING, LLC | 2025-04-10 | — | — | US | disclosed |
| US-20250115635-A1 | LINKER STRUCTURES WITH MINIMAL SCAR FOR ENZYMATIC SYNTHESIS | MICROSOFT TECHNOLOGY LICENSING, LLC | 2025-04-10 | — | — | US | disclosed |
| US-12215121-B2 | Linker structures with minimal scar for enzymatic synthesis | MICROSOFT TECHNOLOGY LICENSING, LLC (US) | 2025-02-04 | — | — | US | disclosed |
| US-12215121-B2 | Linker structures with minimal scar for enzymatic synthesis | MICROSOFT TECHNOLOGY LICENSING, LLC (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4355874-A1 | METHODS OF PREPARING BIVALENT MOLECULES | Insitro, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-4272000-A2 | LINKER STRUCTURES WITH MINIMAL SCAR FOR ENZYMATIC SYNTHESIS | Microsoft Technology Licensing LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-6694267-B2 | DETECTING PREFERENTIAL BIOPOLYMERS IN LIBRARIES; OBTAIN LIBRARY, SCREEN WITH PROBE, SEPARATE LIGAND COMPLEXES, DISSOCIATE COMPLEXES, DETERMINE MASS, RECOVER BIOPOLYMERS | NEOGENESIS DRUG DISCOVERY, INC. | 2004-02-17 | — | — | US | disclosed |
| US-20040014137-A1 | Method for producing and screening mass-coded combinatorial libraries for drug discovery and target validation | NEOGENESIS, INC., A DELAWARE CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20030224409-A1 | Method for producing and screening mass-coded combinatorial libraries for drug discovery and target validation | NEOGENESIS, INC., A DELAWARE CORPORATION | 2003-12-04 | — | — | US | disclosed |
| US-20030138788-A1 | Method for producing and screening mass-coded combinatorial libraries for drug discovery and target validation | NEOGENESIS PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | US | disclosed |
| US-20020182714-A1 | Method for producing and screening mass-coded combinatorial libraries for drug discovery and target validation | NEOGENESIS PHARMACEUTICALS, INC. (US) | 2002-12-05 | — | — | US | disclosed |
| US-20020172970-A1 | Method for producing and screening mass-coded combinatorial libraries for drug discovery and target validation | NEOGENESIS PHARMACEUTICALS, INC. (US) | 2002-11-21 | — | — | US | disclosed |
| WO-2002018540-A2 | PYRIDINE DERIVATIVES USEFUL AS CD40:CD154 BINDING INTERRUPTOR COMPOUNDS AND USE THEREOF TO TREAT IMMUNOLOGICAL COMPLICATIONS | BIOGEN, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6207861-B1 | Method for producing and screening mass coded combinatorial libraries for drug discovery and target validation | NEOGENESIS, INC. | 2001-03-27 | — | — | US | disclosed |
| EP-1045819-A1 | METHOD FOR PRODUCING MASS-CODED COMBINATORIAL LIBRARIES | Neogenesis, Inc. (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035109-A1 | METHOD FOR PRODUCING MASS-CODED COMBINATORIAL LIBRARIES | NEOGENESIS, INC. (US) | 1999-07-15 | — | — | WO | disclosed |